Top

Journal of Cancer Research and Clinical Oncology

Published in:

24-02-2023 | Hepatocellular Carcinoma | Research

Molecular phenotypic linkage between N⁶-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma

Authors: Feng Zhang, Junming Bi, Jiasheng Liao, Wenhui Zhong, Min Yu, Xin Lu, Jinhui Che, Zhiyuan Chen, Haobin Xu, Shixiong Hu, Yubin Liu, Shuijiao Guo

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2023

Abstract

Purpose

The crucial role of N⁶-methyladenosine (m⁶A) methylation in anti-tumor immunity and immunotherapy has been broadly depicted. However, the molecular phenotypic linkages between m⁶A modification pattern and immunological ecosystem are expected to be disentangled in hepatocellular carcinoma (HCC), for immunotherapeutic unresponsiveness circumvention and combination with promising drug agents.

Methods

Modification patterns of m⁶A methylation were qualitatively dissected according to the large-scale HCC samples profiling. We then determined the immune phenotypic linkages by systematically evaluating their tumor microenvironment composition, immune/stromal-relevant signature, immune checkpoints correlation, and prognostic value. Individual quantification of m⁶A methylation pattern was achieved by m⁶Ascore construction, intensified by longitudinal single-cell analysis of immunotherapy cohort and validated by the transcriptomic profiles of our in-hospital GDPH-HCC cohort. Candidate therapeutic agents were also screened out.

Results

Three distinct m⁶A methylation patterns were determined in high accordance with inflamed-, excluded-, and desert-immunophenotype. To be precise, Immune-inflamed high-m⁶Ascore group was characterized by activated immunity with favorable prognosis. Stromal activation and absence of immune cell infiltration were observed in low-m⁶Ascore phenotype, linked to impaired outcome. Patients with low-m⁶Ascore demonstrated diminished responses and clinical benefits for cohorts receiving immunotherapy. The above credible linkage between m⁶A methylation pattern and tumor immune microenvironment was robustly validated in our GDPH-HCC cohort. Single-cell dynamic change of m⁶A methylation level in exhausted CD8 T cell and fibroblast was depicted in immunotherapy cohort fore and art. Derived from m⁶A methylation pattern, seven potential frontline drug agents were recognized as promising choice for high-m⁶Ascore patients.

Conclusion

Our work bridged the credible linkage between epigenetics and anti-tumor immunity in HCC, unraveling m⁶A modification pattern as immunological indicator and predictor for immunotherapy. Individualized m⁶Ascore facilitated strategic choices to maximize therapy-responsive possibility.

Available only for authorised users

Alarcon CR, Lee H, Goodarzi H, Halberg N, Tavazoie SF (2015) N6-methyladenosine marks primary microRNAs for processing. Nature 519(7544):482–485. https://doi.org/10.1038/nature14281CrossRefPubMedPubMedCentral

Batista PJ (2017) The RNA Modification N(6)-methyladenosine and its implications in human disease. Genom Proteom Bioinform 15(3):154–163. https://doi.org/10.1016/j.gpb.2017.03.002CrossRef

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Galon J (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4):782–795. https://doi.org/10.1016/j.immuni.2013.10.003CrossRefPubMed

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Krummel MF (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24(5):541–550. https://doi.org/10.1038/s41591-018-0014-xCrossRefPubMedPubMedCentral

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Trajanoski Z (2017) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 18(1):248–262. https://doi.org/10.1016/j.celrep.2016.12.019CrossRefPubMed

Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541(7637):321–330. https://doi.org/10.1038/nature21349CrossRefPubMed

Chen XY, Zhang J, Zhu JS (2019) The role of m(6)A RNA methylation in human cancer. Mol Cancer 18(1):103. https://doi.org/10.1186/s12943-019-1033-zCrossRefPubMedPubMedCentral

Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Noushmehr H (2016) TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res 44(8):e71. https://doi.org/10.1093/nar/gkv1507CrossRefPubMed

Corsello SM, Nagari RT, Spangler RD, Rossen J, Kocak M, Bryan JG, Golub TR (2020) Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer 1(2):235–248. https://doi.org/10.1038/s43018-019-0018-6CrossRefPubMedPubMedCentral

Dai D, Wang H, Zhu L, Jin H, Wang X (2018) N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis 9(2):124. https://doi.org/10.1038/s41419-017-0129-xCrossRefPubMedPubMedCentral

Edling CE, Selvaggi F, Ghonaim R, Maffucci T, Falasca M (2014) Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. Cancer Biol Ther 15(5):524–532. https://doi.org/10.4161/cbt.28018CrossRefPubMedPubMedCentral

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Melero I (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389(10088):2492–2502. https://doi.org/10.1016/s0140-6736(17)31046-2CrossRefPubMedPubMedCentral

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Investigators IM (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894–1905. https://doi.org/10.1056/NEJMoa1915745CrossRefPubMed

Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V (2020) Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized Double-Blind Phase III Trial Journal of Clinical Oncology 38(3):193–202. https://doi.org/10.1200/JCO.19.01307

Franz M, Rodriguez H, Lopes C, Zuberi K, Montojo J, Bader GD, Morris Q (2018) GeneMANIA update 2018. Nucleic Acids Res 46(W1):W60–W64. https://doi.org/10.1093/nar/gky311CrossRefPubMedPubMedCentral

Gajewski TF (2015) The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment. Semin Oncol 42(4):663–671. https://doi.org/10.1053/j.seminoncol.2015.05.011CrossRefPubMedPubMedCentral

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Investigators K (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–2028. https://doi.org/10.1056/NEJMoa1501824CrossRefPubMed

Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd, Sellers WR (2019) Next-generation characterization of the cancer cell line encyclopedia. Nature 569(7757):503–508. https://doi.org/10.1038/s41586-019-1186-3CrossRefPubMedPubMedCentral

Gu Y, Wu X, Zhang J, Fang Y, Pan Y, Shu Y, Ma P (2021) The evolving landscape of N(6)-methyladenosine modification in the tumor microenvironment. Mol Ther 29(5):1703–1715. https://doi.org/10.1016/j.ymthe.2021.04.009CrossRefPubMedPubMedCentral

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Ribas A (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134–144. https://doi.org/10.1056/NEJMoa1305133CrossRefPubMedPubMedCentral

Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, He C (2019) Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells. Nature 566(7743):270–274. https://doi.org/10.1038/s41586-019-0916-xCrossRefPubMedPubMedCentral

Hanzelmann SCR, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinform. https://doi.org/10.1186/1471-2105-14-7CrossRef

He L, Jang JH, Choi HG, Lee SM, Nan MH, Jeong SJ, Kim BY (2013) Oligomycin A enhances apoptotic effect of TRAIL through CHOP-mediated death receptor 5 expression. Mol Carcinog 52(2):85–93. https://doi.org/10.1002/mc.21831CrossRefPubMed

He L, Li H, Wu A, Peng Y, Shu G, Yin G (2019) Functions of N6-methyladenosine and its role in cancer. Mol Cancer 18(1):176. https://doi.org/10.1186/s12943-019-1109-9CrossRefPubMedPubMedCentral

He X, Tan L, Ni J, Shen G (2021) Expression pattern of m(6)A regulators is significantly correlated with malignancy and antitumor immune response of breast cancer. Cancer Gene Ther 28(3–4):188–196. https://doi.org/10.1038/s41417-020-00208-1CrossRefPubMed

Hegde PS, Karanikas V, Evers S (2016) The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res 22(8):1865–1874. https://doi.org/10.1158/1078-0432.CCR-15-1507CrossRefPubMed

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567. https://doi.org/10.1038/nature14011CrossRefPubMedPubMedCentral

Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8(1):118–127. https://doi.org/10.1093/biostatistics/kxj037CrossRefPubMed

Joyce JAF, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74–80CrossRefPubMed

Jung H, Kim HS, Kim JY, Sun JM, Ahn JS, Ahn MJ, Choi JK (2019) DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat Commun 10(1):4278. https://doi.org/10.1038/s41467-019-12159-9CrossRefPubMedPubMedCentral

Kim JM, Chen DS (2016) Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure) Annals of Oncology 27(8) 1492-1504. https://doi.org/10.1093/annonc/mdw217

Kim JY, Choi JK, Jung H (2020) Genome-wide methylation patterns predict clinical benefit of immunotherapy in lung cancer. Clin Epigenetics 12(1):119. https://doi.org/10.1186/s13148-020-00907-4CrossRefPubMedPubMedCentral

Li Q, Ni Y, Zhang L, Jiang R, Xu J, Yang H, Wang X (2021) HIF-1alpha-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation. Signal Transduct Target Ther 6(1):76. https://doi.org/10.1038/s41392-020-00453-8CrossRefPubMedPubMedCentral

Liu Q, Zhang H, Jiang X, Qian C, Liu Z, Luo D (2017) Factors involved in cancer metastasis: a better understanding to “seed and soil” hypothesis. Mol Cancer 16(1):176. https://doi.org/10.1186/s12943-017-0742-4CrossRefPubMedPubMedCentral

Ma JZ, Yang F, Zhou CC, Liu F, Yuan JH, Wang F, Sun SH (2017) METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6)-methyladenosine-dependent primary MicroRNA processing. Hepatology 65(2):529–543. https://doi.org/10.1002/hep.28885CrossRefPubMed

Ma L, Hernandez MO, Zhao Y, Mehta M, Tran B, Kelly M, Wang XW (2019) Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. Cancer Cell 36(4):418-430 e416. https://doi.org/10.1016/j.ccell.2019.08.007CrossRefPubMedPubMedCentral

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Powles T (2018) TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544–548. https://doi.org/10.1038/nature25501CrossRefPubMedPubMedCentral

Muller S, Glass M, Singh AK, Haase J, Bley N, Fuchs T, Huttelmaier S (2019) IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner. Nucleic Acids Res 47(1):375–390. https://doi.org/10.1093/nar/gky1012CrossRefPubMed

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Alizadeh AA (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12(5):453–457. https://doi.org/10.1038/nmeth.3337CrossRefPubMedPubMedCentral

Pan Y, Ma P, Liu Y, Li W, Shu Y (2018) Multiple functions of m(6)A RNA methylation in cancer. J Hematol Oncol 11(1):48. https://doi.org/10.1186/s13045-018-0590-8CrossRefPubMedPubMedCentral

Panagi M, Voutouri C, Mpekris F, Papageorgis P, Martin MR, Martin JD, Stylianopoulos T (2020) TGF-beta inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity. Theranostics 10(4):1910–1922. https://doi.org/10.7150/thno.36936CrossRefPubMedPubMedCentral

Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, Guttman M, Jaffrey SR (2016) m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature 537(7620):369–373. https://doi.org/10.1038/nature19342CrossRefPubMedPubMedCentral

Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, Schreiber SL (2016) Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol 12(2):109–116. https://doi.org/10.1038/nchembio.1986CrossRefPubMed

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):e47. https://doi.org/10.1093/nar/gkv007CrossRefPubMedPubMedCentral

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dreicer R (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387(10031):1909–1920. https://doi.org/10.1016/s0140-6736(16)00561-4CrossRefPubMedPubMedCentral

Roundtree IA, Evans ME, Pan T, He C (2017) Dynamic RNA modifications in gene expression regulation. Cell 169(7):1187–1200. https://doi.org/10.1016/j.cell.2017.05.045CrossRefPubMedPubMedCentral

Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, Donnadieu E (2012) Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 122(3):899–910. https://doi.org/10.1172/JCI45817CrossRefPubMedPubMedCentral

Shulman Z, Stern-Ginossar N (2020) The RNA modification N(6)-methyladenosine as a novel regulator of the immune system. Nat Immunol 21(5):501–512. https://doi.org/10.1038/s41590-020-0650-4CrossRefPubMed

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Chan TA (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371(23):2189–2199. https://doi.org/10.1056/NEJMoa1406498CrossRefPubMedPubMedCentral

Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, Chen J (2020) Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell 38(1):79-96 e11. https://doi.org/10.1016/j.ccell.2020.04.017CrossRefPubMedPubMedCentral

Su R, Dong L, Li Y, Gao M, He PC, Liu W, Chen J (2022) METTL16 exerts an m(6)A-independent function to facilitate translation and tumorigenesis. Nat Cell Biol 24(2):205–216. https://doi.org/10.1038/s41556-021-00835-2CrossRefPubMedPubMedCentral

Sun D, Wang J, Han Y, Dong X, Ge J, Zheng R, Wang C (2021) TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res 49(D1):D1420–D1430. https://doi.org/10.1093/nar/gkaa1020CrossRefPubMed

Sztiller-Sikorska M, Czyz M (2020) Parthenolide as cooperating agent for anti-cancer treatment of various malignancies. Pharmaceuticals (basel). https://doi.org/10.3390/ph13080194CrossRefPubMed

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Shmulevich I (2018) The immune landscape of cancer. Immunity 48(4):812-830 e814. https://doi.org/10.1016/j.immuni.2018.03.023CrossRefPubMedPubMedCentral

Topalian SL, Stephen HF, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al (2012) Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med 366:2443–2454CrossRefPubMedPubMedCentral

Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16(5):275–287. https://doi.org/10.1038/nrc.2016.36CrossRefPubMedPubMedCentral

Wagner GP, Kin K, Lynch VJ (2012) Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples. Theory Biosci 131(4):281–285. https://doi.org/10.1007/s12064-012-0162-3CrossRefPubMed

Wilkerson MD, Hayes DN (2010) ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26(12):1572–1573. https://doi.org/10.1093/bioinformatics/btq170CrossRefPubMedPubMedCentral

Xi X, Liu N, Wang Q, Chu Y, Yin Z, Ding Y, Lu Y (2019) ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma. Cell Death Dis 10(10):757. https://doi.org/10.1038/s41419-019-1986-2CrossRefPubMedPubMedCentral

Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR (2019a) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16(10):589–604. https://doi.org/10.1038/s41575-019-0186-yCrossRefPubMedPubMedCentral

Yang S, Wei J, Cui YH, Park G, Shah P, Deng Y, He YY (2019b) m(6)A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun 10(1):2782. https://doi.org/10.1038/s41467-019-10669-0CrossRefPubMedPubMedCentral

Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Kudo M (2019) Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced Asian cohort analysis. J Hepatol 71(3):543–552. https://doi.org/10.1016/j.jhep.2019.05.014CrossRefPubMed

Yi M, Nissley DV, McCormick F, Stephens RM (2020) ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications. Sci Rep 10(1):10258. https://doi.org/10.1038/s41598-020-66986-8CrossRefPubMedPubMedCentral

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Verhaak RG (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4:2612. https://doi.org/10.1038/ncomms3612CrossRefPubMed

Zaccara S, Ries RJ, Jaffrey SR (2019) Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol 20(10):608–624. https://doi.org/10.1038/s41580-019-0168-5CrossRefPubMed

Zanotto-Filho A, Braganhol E, Schroder R, de Souza LH, Dalmolin RJ, Pasquali MA, Moreira JC (2011) NFkappaB inhibitors induce cell death in glioblastomas. Biochem Pharmacol 81(3):412–424. https://doi.org/10.1016/j.bcp.2010.10.014CrossRefPubMed

Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL (2020a) m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer 19(1):53. https://doi.org/10.1186/s12943-020-01170-0CrossRefPubMedPubMedCentral

Zhang C, Zhang G, Sun N, Zhang Z, Xue L, Zhang Z, He J (2020b) An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma. Signal Transduct Target Ther 5(1):182. https://doi.org/10.1038/s41392-020-00221-8CrossRefPubMedPubMedCentral

Zhang X, Shi M, Chen T, Zhang B (2020c) Characterization of the immune cell infiltration landscape in head and neck squamous cell carcinoma to aid immunotherapy. Mol Ther Nucleic Acids 22:298–309. https://doi.org/10.1016/j.omtn.2020.08.030CrossRefPubMedPubMedCentral

Zhao BS, Roundtree IA, He C (2017) Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol 18(1):31–42. https://doi.org/10.1038/nrm.2016.132CrossRefPubMed

Title: Molecular phenotypic linkage between N6-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma
Authors: Feng Zhang
Junming Bi
Jiasheng Liao
Wenhui Zhong
Min Yu
Xin Lu
Jinhui Che
Zhiyuan Chen
Haobin Xu
Shixiong Hu
Yubin Liu
Shuijiao Guo
Publication date: 24-02-2023
Publisher: Springer Berlin Heidelberg
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Epigenetics
Published in: Journal of Cancer Research and Clinical Oncology / Issue 10/2023
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-04589-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2023

Mitotic phosphorylation of Tau/MAPT modulates cell cycle progression in prostate cancer cells

Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features

Decreased expression of prolyl hydroxylase 1 is associated with poor prognosis in colorectal cancers

Heterodimerization of cholecystokinin 1 and cholecystokinin 2 receptors in gallbladder cancer: a new mechanism for carcinogenesis

Ovarian cancer prevention by opportunistic salpingectomy is a new de facto standard in Germany

The relationship of airflow limitation with lung squamous cell carcinoma: evidence from mendelian randomization analysis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials